Cellectar Biosciences, Inc.
CLRB
|
$3.02
-0.66%
-0.66%
810K
|
Health Technology
(0.0% 1d) (-21.7% 1m) (104.7% 1y) (0.0% 2d) (0.0% 3d) (-8.7% 7d) (5.92% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 97,426,740
http://www.cellectar.com
Sec Filling | Patents | 8 employees
(US) Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
cancer optical treatment
add to watch list Paper trade email alert is off
Press-releases
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: -0.52%
H: 1.31%
C: -5.09%
year update financial results
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 0.53%
H: 1.32%
C: -1.84%
conference year results
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 1.19%
H: 5.59%
C: 5.59%
million
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: -0.57%
H: 8.88%
C: 6.02%
tumors pipeline preclinical therapy
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Published: 2024-01-12 (Crawled : 12:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: -1.16%
H: 5.0%
C: 3.24%
conference topline results
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Published: 2024-01-11 (Crawled : 12:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 0.86%
H: 2.0%
C: -1.71%
treatment
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
Published: 2024-01-03 (Crawled : 13:30) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 3.15%
H: 6.1%
C: -4.07%
trial
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Published: 2023-12-19 (Crawled : 13:30) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 5.93%
H: 3.36%
C: -2.99%
research collaboration
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Published: 2023-12-12 (Crawled : 13:30) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: -2.33%
H: 5.56%
C: 3.97%
platform
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 5.04%
H: 2.8%
C: -4.0%
conference week trial
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10